Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | IDE | P14735 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.61 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.59 |
| ▸ | HLCS | P50747 | 2/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171661 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL565479 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL383254 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL16913029 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL3143245 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL25417015 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1270494 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL18257230 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL22975316 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL565248 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385998-A1 | BIOMOLECULE CHARACTERIZATION USING MASS SPECTROMETRY AND AFFINITY TAGS | Ciphergen Biosystems, Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030077616-A1 | Biomolecule characterization using mass spectrometry and affinity tags | CIPHERGEN BIOSYSTEMS, INC. (US) | 2003-04-24 | — | — | US | claimed |
| WO-2002086168-A1 | BIOMOLECULE CHARACTERIZATION USING MASS SPECTROMETRY AND AFFINITY TAGS | CIPHERGEN BIOSYSTEMS, INC. (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2024191684-A1 | DETECTION OF HEPATITIS C VIRUS RIBONUCLEIC ACID FROM WHOLE BLOOD USING REVERSE TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-116381214-A | Light-activated chemiluminescence detection kit, and use method and application thereof | 科美博阳诊断技术(上海)有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| WO-2022056078-A1 | RNASE H-ASSISTED DETECTION ASSAY FOR RNA (RADAR) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-17 | — | — | WO | disclosed |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2021-06-15 | — | — | US | disclosed |
| US-20190085372-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2019-03-21 | — | — | US | disclosed |
| EP-3430015-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | Oryzon Genomics, S.A. (ES) | 2019-01-23 | — | — | EP | disclosed |
| US-10071990-B2 | Site-specific orthogonal labeling of the carboxy terminus of α-tubulin in live cells | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-09-11 | — | — | US | disclosed |
| EP-0643706-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR BINDING BIO-AFFECTING SUBSTANCES TO SURFACE MEMBRANES OF BIO-PARTICLES | Zynaxis Inc. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0643706-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR BINDING BIO-AFFECTING SUBSTANCES TO SURFACE MEMBRANES OF BIO-PARTICLES. | ZYNAXIS INC (US) | 1994-12-27 | — | — | EP | disclosed |
| EP-0618891-A1 | METHOD FOR MAKING VALPROIC ACID DERIVATIVES | BECKMAN INSTRUMENTS, INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| US-5326692-A | Polyazaindacene dyes | MOLECULAR PROBES, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| EP-0596098-A1 | FLUORESCENT MICROPARTICLES WITH CONTROLLABLE ENHANCED STOKES SHIFT | MOLECULAR PROBES, INC. (US) | 1994-05-11 | — | — | EP | disclosed |
| US-5306824-A | Enzyme inhibitors; purifying proteins | GEORGIA TECH RESEARCH CORPORATION (US) | 1994-04-26 | — | — | US | disclosed |
| WO-1994006745-A1 | METHOD FOR MAKING VALPROIC ACID DERIVATIVES | BECKMAN INSTRUMENTS, INC. (US) | 1994-03-31 | — | — | WO | disclosed |
| WO-1993023492-A1 | FLUORESCENT MICROPARTICLES WITH CONTROLLABLE ENHANCED STOKES SHIFT | MOLECULAR PROBES, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993011120-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR BINDING BIO-AFFECTING SUBSTANCES TO SURFACE MEMBRANES OF BIO-PARTICLES | ZYNAXIS TECHNOLOGIES, INCORPORATED (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | TDP1 1918/4885MEN1 2238/4885ABL1 1425/4885 |
| US-10071990-B2 | Site-specific orthogonal labeling of the carboxy terminus of α-tubulin in live cells | TUBB, TUBA1C, TUBB1 | TDP1 396/4885MEN1 4243/4885ABL1 659/4885 |
| US-20190085372-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | TDP1 1918/4885MEN1 2238/4885ABL1 1425/4885 |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | TDP1 1918/4885MEN1 2238/4885ABL1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.